https://www.selleckchem.com/pr....oducts/gsk2643943a.h
Late-life CVRFs were associated with declines in early late life (80 years) but with gains in very late life (≥80 years). After adjusting for CVRF exposures at all time periods, the associations for early adult and late-life CVRFs persisted. We found that imputed CVRFs across the life course, especially in early adulthood, were associated with greater late-life cognitive decline. Our results suggest that CVRF treatment in early adulthood could benefit late-life cognition, but that treatment in very late life may not be as helpfu
Like
Comment
Share
